Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater China
January 3, 2012
Palo Alto, CA - Vivo Ventures, a healthcare investment firm with
offices in Palo Alto, California, Shanghai, and Chengdu, China, announced
the final closing of Vivo Ventures VII ("Vivo VII") at $375 million, which
brings the firm's total funds under management to more than $1 billion.
Vivo plans to invest the capital primarily in later development
stage pharmaceutical and medical device companies in the U.S. and in
revenue stage healthcare companies in greater China. As an early entrant
to the Chinese healthcare market, Vivo plans to continue assisting
companies in both countries in their efforts to forge cross-border
partnerships, enabling companies to acquire new products and expand the
market for their existing products. Vivo also intends to continue its
successful strategies of building companies from scratch, identifying
later stage products with a high probability of FDA approval, and
investing directly in public companies.
Vivo's recent IPOs and
exits include Sagent (IPO, Nasdaq), China Kanghui (IPO, NYSE), Vicept
(acquired by Allergan), Bioform (acquired by Merz), as well as investments
in Avanir Pharmaceuticals (Nasdaq), Acura Pharmaceuticals (Nasdaq), Lee's
Pharm (HKEx), and Achillion Pharmaceuticals (Nasdaq).
partners of Vivo VII are Drs. Frank Kung, Albert Cha, Edgar Engleman, Chen
Yu, and James Zhao. Investors in the Vivo VII include pension funds, funds
of funds, university endowments, foundations, financial institutions, and
family offices. In addition to limited partners that participated in
Vivo's earlier funds, Vivo VII added a number of new institutional
investors from the U.S., Europe, and Asia.
Founded in 1996, Vivo Ventures is a healthcare
investment firm focused on investing in and building high quality
companies in the U.S. and China. With more than $1 billion under
management, Vivo employs a unique multi-pronged strategy of identifying
and working with companies with promising later development stage products
in the U.S. and revenue stage companies in China. Vivo Ventures has
offices in Palo Alto, California, Shanghai, China, and Chengdu, China.